Wanbury working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

58.29×	58.29×	45.68×	34.98×	43.25×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
72.25×	72.25×	61.98×	49.91×	47.77×
162.17×	162.17×	85.81×	89.22×	204.51×
−31.63×	−31.63×	21.85×	−4.33×	−113.49×
17.39×	17.33×	31.84×	−10.50×	−2.89×
1.40×	1.40×	1.58×	1.78×	1.53×
0.48×	0.48×	0.85×	0.13×	−1.90×
0.30×	0.30×	0.34×	0.06×	0.85×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

WANBURY₹181.93

Wanbury Limited

· Pharma & Health

₹ CrorePeersAHCL ANUHPHR BAJAJHCARE THEMISMED ZIMLAB LINCOLN SIGACHI VALIANTLABMcap ₹636 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	43.25	34.98	45.68	58.29	58.29
Receivable Days (DSO)	47.77	49.91	61.98	72.25	72.25
Payable Days (DPO)	204.51	89.22	85.81	162.17	162.17
Cash Conversion Cycle (days)	-113.49	-4.33	21.85	-31.63	-31.63
Working Capital Turnover	-2.89	-10.50	31.84	17.33	17.39
Asset Turnover	1.53	1.78	1.58	1.40	1.40
Cash Conversion (CFO/Net Income)	-1.90	0.13	0.85	0.48	0.48
CFO/EBITDA	0.85	0.06	0.34	0.30	0.30

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.